Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gliomas were assigned to one of the three molecular groups: Group O (IDH-mutant, 1p/19q co-deleted oligodendrogliomas, n = 95), Group A (IDH-mutant, ATRX inactivated astrocytomas, n = 175) and Group G (IDH wild-type, GBM-like, n = 46).
|
30536195 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1-R132H and 1p19q loss were found only in 12 out of the 13 oligodendrogliomas (P<0.0001).
|
27389560 |
2016 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oligodendrogliomas with a mutant IDH1 had noteworthy enhanced expression of enzymes controlling aerobic glycolysis and detoxification, and anti-apoptosis proteins.
|
21898821 |
2011 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant.
|
30710203 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III.
|
19554337 |
2009 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several studies on molecular profiling of oligodendrogliomas (OGs) in adults have shown a distinctive genetic pattern characterized by combined deletions of chromosome arms 1p and 19q, O6-methylguanine-methyltransferase (MGMT) methylation, and isocitrate dehydrogenase 1 (IDH1) mutation, which have potential diagnostic, prognostic, and even therapeutic relevance.
|
21937591 |
2011 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Next-generation molecular biology technologies have recently identified recurrent CIC and FUBP1 point mutations in 1p/19q codeleted and IDH-mutated oligodendrogliomas.
|
22913971 |
2012 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<i>TERT</i> promoter mutations are selectively observed among 1p/19q-codeleted oligodendrogliomas and isocitrate dehydrogenase gene- <i>(IDH-)</i> wildtype glioblastoma (GBM).
|
29693015 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 or IDH2 mutations were frequently in oligodendrogliomas (67%), anaplastic astrocytomas (62%), anaplastic oligoastrocytomas (75%), anaplastic oligodendrogliomas (50%), secondary glioblastomas (67%), gangliogliomas (38%), and anaplastic gangliogliomas (60%).
|
19765000 |
2009 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%).
|
18985363 |
2008 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The first of these enzymes is isocitrate dehydrogenase 1 (IDH1), which is mutated in secondary glioblastomas and ~70% of grade II/III astrocytomas and oligodendrogliomas.
|
23432648 |
2013 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We excluded glioblastoma-like tumors (7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas with concurrent 1p/19q co-deletion and IDH mutation (1p/19q subgroup) from those with predominant IDH mutation alone (IDHme subgroup).
|
29631562 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas.
|
19996293 |
2009 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype.
|
29468261 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, identification of a common IDH1 mutation in enchondroma and oligodendroglioma-matched pair specimens supports the hypothesis that IDH1/2 mosaicism initiates tumorigenesis.
|
29224049 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationship between 3 hypoxic markers, carbonic anhydrase-9 (CA-9), hypoxia-inducible factor (HIF)-1α, and HIF-2α and the traditional genetic markers, deletions of chromosomes 1p and 19q and Isocitrate dehydrogenase 1 (IDH1) R132H mutation in oligodendrogliomas.
|
26960282 |
2016 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1(R132) mutation was most frequent in oligodendrogliomas (57/62, 91.9%), with IDH1(R132H) mutation as the most frequent mutation form.
|
27780605 |
2016 |
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, IDH and TERTp co-occurred in 75% of 1p/19q intact, TP53 wild-type oligodendrogliomas, highlighting the potential of the co-mutations in assisting diagnosis of oligodendrogliomas in tumors with clear cell morphology and non-codeleted 1p/19q status.
|
27556304 |
2016 |
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel).
|
29186201 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The relationship between chromosome 1p and 19q deletions and treatment responsive oligodendrogliomas is discussed, as are the newer advances relating to silencing of the MGMT gene in astrocytomas and mutations in the IDH-1 gene in both astrocytomas and oligodendrogliomas.
|
21233669 |
2011 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
36 (57%) had oligodendroglioma and 27 astrocytoma.IDH-1 mutation was present in 53 (84%).
|
30292978 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 25th, 50th, 75th, and 90th percentiles of MK and average MK showed significant differences between IDH1/2<sub>wild-type</sub> gliomas, IDH1/2<sub>mutated</sub> gliomas, and oligodendrogliomas with chromosome 1p/19q loss of heterozygosity and IDH1/2<sub>mutation</sub> (p<0.001).
|
28987669 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Most tumors have a missense mutation for IDH1 combined with 1p19q codeletion in oligodendrogliomas or ATRX/TP53 mutations in astrocytomas.
|
29027701 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
|
21069360 |
2011 |